MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Cardium Therapeutics, Inc. (CXM) CSO Dr. Rubanyi Authors Generx Publication In Molecular Therapy 0 comments
    May 2, 2013 1:55 PM | about stocks: CXM

    Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, today highlighted the publication, "Mechanistic, Technical, and Clinical Perspectives in Therapeutic Stimulation of Coronary Collateral Development by Angiogenic Growth Factors," authored by Gabor M Rubanyi, M.D., Ph.D., Cardium's chief scientific officer in the April issue of Molecular Therapy.

    The publication frameworks the mechanistic basis of adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and the optimization of clinical trial designs, including information on designating appropriate clinical trial endpoints, selecting patients who are likely responders to therapeutic stimulation of collateral development, and potential genetic and molecular markers in patient screening.

    Dr. Rubanyi also summarizes the knowledge gained in the last 15 years of pre-clinical and clinical research and development initiatives in the field of therapeutic angiogenesis using growth factor proteins and genes.

    "I also described in some detail the specific insights that our team, first at Schering AG (now part of Bayer Healthcare) and now at Cardium, has gained in the course of the development of Generx, one of the most advanced therapeutic angiogenesis product candidates," Dr. Rubanyi stated in the press release. "These lessons have been invaluable and they have been incorporated into the trial design of the Generx ASPIRE pivotal phase 3 clinical study now underway at several leading cardiovascular centers in the Russian Federation."

    Generx is Cardium's interventional cardiology-focused product candidate currently in development as a non-surgical option for the treatment of a medical condition termed cardiac microvascular insufficiency (NYSE:CMI).

    The abstract of the publication is available at nature.com/mt/journal/v21/n4/abs/mt20131... (membership required for full viewing). The company will mail the full article to interested parties upon request by contacting Cardium at 858-436-1000.

    For more information visit cardiumthx.com

    Please see disclaimer on the MissionIR website www.missionir.com/disclaimer.html

    Stocks: CXM
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.